Geode Capital Management LLC Has $2.04 Million Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)

Geode Capital Management LLC trimmed its holdings in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 1.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 490,239 shares of the company’s stock after selling 5,378 shares during the quarter. Geode Capital Management LLC’s holdings in MeiraGTx were worth $2,044,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MGTX. Barclays PLC grew its holdings in MeiraGTx by 107.1% in the 3rd quarter. Barclays PLC now owns 147,827 shares of the company’s stock valued at $618,000 after buying an additional 76,437 shares during the last quarter. State Street Corp boosted its position in shares of MeiraGTx by 0.9% in the third quarter. State Street Corp now owns 574,727 shares of the company’s stock valued at $2,397,000 after acquiring an additional 5,251 shares during the period. Garden State Investment Advisory Services LLC acquired a new stake in shares of MeiraGTx in the third quarter worth $1,636,000. Erste Asset Management GmbH bought a new position in MeiraGTx during the third quarter worth $2,795,000. Finally, Knoll Capital Management LLC acquired a new position in MeiraGTx during the 3rd quarter valued at $5,212,000. 67.48% of the stock is currently owned by institutional investors.

MeiraGTx Stock Up 0.2 %

NASDAQ MGTX opened at $6.35 on Thursday. The stock has a market capitalization of $496.27 million, a P/E ratio of -5.25 and a beta of 1.26. MeiraGTx Holdings plc has a 52 week low of $3.85 and a 52 week high of $7.37. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. The stock has a fifty day moving average of $6.27 and a 200-day moving average of $5.12.

Analyst Ratings Changes

A number of research analysts have recently commented on MGTX shares. Royal Bank of Canada upped their price objective on shares of MeiraGTx from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Chardan Capital reaffirmed a “buy” rating and issued a $36.00 price target on shares of MeiraGTx in a report on Monday, November 18th.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.